Neurocognitive Risk With PCSK9 Inhibitors

被引：3
|
作者：
Khan, Abdur Rahman [1 ]
Riaz, Haris [1 ]
Farid, Talha [1 ]
Bolli, Roberto [1 ]
机构：
[1] Univ Louisville, Dept Med, Div Cardiovasc Med, 200 Abraham Flexner Way, Louisville, KY 40202 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2017年 / 69卷 / 19期
基金：
美国国家卫生研究院;
关键词：
CARDIOVASCULAR EVENTS; REDUCING LIPIDS; SAFETY; ALIROCUMAB; EFFICACY;
D O I：
10.1016/j.jacc.2017.02.063
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2468 / 2469
页数：3
相关论文
共 50 条
  • [1] Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis
    Gouverneur, Amandine
    Sanchez-Pena, Paola
    Veyrac, Gwenaelle
    Salem, Joe-Elie
    Begaud, Bernard
    Bezin, Julien
    CARDIOVASCULAR DRUGS AND THERAPY, 2023, 37 (02) : 271 - 276
  • [2] PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
    Vicente-Valor, Juan
    Garcia-Gonzalez, Xandra
    Ibanez-Garcia, Sara
    Duran-Garcia, Maria Esther
    de Lorenzo-Pinto, Ana
    Rodriguez-Gonzalez, Carmen
    Mendez-Fernandez, Irene
    Percovich-Hualpa, Juan Carlos
    Herranz-Alonso, Ana
    Sanjurjo-Saez, Maria
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 146
  • [3] Safety of PCSK9 inhibitors
    Grzesk, Grzegorz
    Dorota, Bednarska
    Wolowiec, Lukasz
    Wolowiec, Anna
    Osiak, Joanna
    Kozakiewicz, Mariusz
    Banach, Joanna
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 156
  • [4] PCSK9 Inhibitors: A Technology Worth Paying For?
    Weintraub, William S.
    Gidding, Samuel S.
    PHARMACOECONOMICS, 2016, 34 (03) : 217 - 220
  • [5] A Comprehensive Review of PCSK9 Inhibitors
    Coppinger, Caroline
    Movahed, Mohammad Reza
    Azemawah, Veronica
    Peyton, Lee
    Gregory, James
    Hashemzadeh, Mehrnoosh
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022, 27
  • [6] JCL roundtable: PCSK9 inhibitors in clinical practice
    Brown, W. Virgil
    Moriarty, Patrick M.
    McKenney, James M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (01) : 5 - 14
  • [7] Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia
    Papademetriou, Vasilios
    Stavropoulos, Konstantinos
    Papadopoulos, Christodoulos
    Koutsampasopoulos, Konstantinos
    Dimitriadis, Kiriakos
    Tsioufis, Kostas
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (31) : 3347 - 3653
  • [8] Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk
    Milionis, Haralampos
    Barkas, Fotios
    Ntaios, George
    Papavasileiou, Vasileios
    Vemmos, Kostantinos
    Michel, Patrick
    Elisaf, Moses
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 34 : 54 - 57
  • [9] Cholestrol and stroke: Roll of PCSK9 inhibitors
    Castilla-Guerra, L.
    Fernandez-Moreno, M. C.
    Rico-Corral, M. A.
    NEUROLOGIA, 2019, 34 (03): : 198 - 203
  • [10] Cholesterol Management in the Era of PCSK9 Inhibitors
    Svatikova, Anna
    Kopecky, Stephen L.
    CURRENT CARDIOLOGY REPORTS, 2017, 19 (09)
12345